US 12,459,923 B2
Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
Guoqiang Wang, Belmont, MA (US); Ruichao Shen, Belmont, MA (US); Brett Granger, Sudbury, MA (US); Jing He, Somerville, MA (US); Xuechao Xing, Wilmington, MA (US); Yong He, Lexington, MA (US); Jiang Long, Wayland, MA (US); Jun Ma, Wayland, MA (US); Bin Wang, Newton, MA (US); and Yat Sun Or, Waltham, MA (US)
Assigned to Enanta Pharmaceuticals, Inc., Watertown, MA (US)
Filed by ENANTA PHARMACEUTICALS, INC., Watertown, MA (US)
Filed on Oct. 26, 2023, as Appl. No. 18/383,949.
Application 17/228,815 is a division of application No. 16/400,529, filed on May 1, 2019, granted, now 11,008,304, issued on May 18, 2021.
Application 18/383,949 is a continuation of application No. 17/228,815, filed on Apr. 13, 2021, granted, now 11,834,436.
Claims priority of provisional application 62/665,789, filed on May 2, 2018.
Prior Publication US 2024/0132476 A1, Apr. 25, 2024
Prior Publication US 2024/0228464 A9, Jul. 11, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 401/14 (2006.01); C07D 405/14 (2006.01); C07D 409/14 (2006.01); C07D 413/14 (2006.01); C07D 417/14 (2006.01)
CPC C07D 401/14 (2013.01) [C07D 405/14 (2013.01); C07D 409/14 (2013.01); C07D 413/14 (2013.01); C07D 417/14 (2013.01)] 12 Claims
 
1. A compound represented by Formula I or a pharmaceutically acceptable salt or ester thereof:

OG Complex Work Unit Chemistry
wherein

OG Complex Work Unit Chemistry
R1 is trifluoromethyl, isopropyl, cyclopropyl or t-butyl;

OG Complex Work Unit Chemistry
R2 is
X is N or C-R3;
R3 is fluorine or methoxy; and
R4 is methyl, difluoromethyl or trifluoromethyl.